Disease-specific risk for an osteonecrosis of the jaw under bisphosphonate therapy.
OBJECTIVE
Osteonecrosis of the jaw (ONJ) presents a severe side-effect of intravenous bisphosphonate (i.v. BP) treatment; yet, the pathoethiological influence of the underlying disease which indicated that treatment remains unclear.


METHODS
We studied a large register of subjects who suffered an ONJ (n = 356) under i.v. BP therapy and characterized them according to underlying diseases and BP intake. By using claims data, we analysed indications in the general public in a cohort of new users of i.v. BPs (n = 1,075) in ambulatory care. For the years 2004-2006, both data sources were compared to indirectly assess the disease-specific risk for the development of an ONJ. We further assessed disease-specific survival after treatment initiation.


RESULTS
Patients with multiple myeloma were found more often, in the ONJ register, than were treated in real life (males: 36.4% vs. 16.2%; females: 27.8% vs. 6.5%) while the proportions of patients with prostate or breast cancer were as expected, and malignancies with low survival rates were strongly underrepresented. No patients with osteoporosis were reported to the ONJ register despite accounting for 18.8% of all the treated females in the general public.


CONCLUSIONS
The pattern of diagnoses that indicated i.v. BP treatment in patients who suffered an ONJ is different from what would be expected when looking at indications in the general public. Each underlying disease may, hence, have its own inherent risk to develop an ONJ due to varying life-expectancies and overall oncological treatment regimes including the interval and type of i.v. BP application.
Jung
Tatjana I
TI
Centre of Muscle and Bone Research (ZMK), Charité University Medicine, Campus Benjamin Franklin, Hindenburgdamm 130, 12200, Berlin, Germany. tatjana.jung@charite.de
Hoffmann
Falk
F
Glaeske
Gerd
G
Felsenberg
Dieter
D
D017668:Age of Onset; D000368:Aged; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D004198:Disease Susceptibility / Q000453:epidemiology / Q000209:etiology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007571:Jaw Diseases / Q000139:chemically induced / Q000453:epidemiology / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000401:mortality; D010020:Osteonecrosis / Q000139:chemically induced / Q000453:epidemiology / Q000209:etiology*; D012042:Registries; D012307:Risk Factors; D016019:Survival Analysis
D050071:Bone Density Conservation Agents; D004164:Diphosphonates
Oncology. 2009;76(3):209-11
19212145
J Oral Maxillofac Surg. 2004 May;62(5):527-34
15122554
J Bone Miner Res. 2008 Jun;23(6):826-36
18558816
J Clin Epidemiol. 2006 Oct;59(10):1110-4
16980152
J Oral Maxillofac Surg. 2003 Sep;61(9):1115-7
12966493
Ann Oncol. 2009 Mar;20(3):600-1
19188135
Ann Oncol. 2009 Aug;20(8):1303-17
19465418
Clin Lymphoma Myeloma. 2008 Apr;8(2):111-6
18501105
J Natl Cancer Inst. 2007 Jul 4;99(13):1016-24
17596574
Cancer. 2000 Jun 15;88(12 Suppl):2961-78
10898340
J Am Dent Assoc. 2008 Jan;139(1):23-30
18167381
J Oral Maxillofac Surg. 2007 Jul;65(7):1328-31
17577497
Bone. 1996 Feb;18(2):75-85
8833200
Oral Oncol. 2008 Sep;44(9):857-69
18282788
Bone. 2009 Jan;44(1):4-10
18948230
Clin Cancer Res. 2003 Aug 1;9(8):2893-7
12912933
Blood. 1999 Jan 1;93(1):300-5
9864174
J Oral Maxillofac Surg. 2006 Jun;64(6):917-23
16713806
Br J Haematol. 2007 Sep;138(5):563-79
17686051
Eur J Clin Pharmacol. 2002 Feb;57(12):883-90
11936708
Haematologica. 2006 Jul;91(7):968-71
16757414
J Bone Miner Res. 2007 Oct;22(10):1479-91
17663640
Pharmacoepidemiol Drug Saf. 2008 Sep;17(9):896-903
18666268
J Clin Oncol. 2006 Mar 20;24(9):1475-7
16549843
Eur Urol. 2008 Nov;54(5):1066-72
18602738
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Aug;104(2):186-93
17448709
Cancer Res. 2002 Nov 15;62(22):6538-44
12438248
Expert Opin Investig Drugs. 2005 Jan;14(1):45-55
15709921
J Evid Based Dent Pract. 2009 Mar;9(1):13-5
19269608
Med Oral Patol Oral Cir Bucal. 2007 Aug 01;12(4):E336-40
17664922
Leukemia. 2007 Jul;21(7):1545-8
17410188
Ortop Traumatol Rehabil. 2003 Apr 30;5(2):223-6
18034010
J Clin Oncol. 2005 Dec 1;23(34):8580-7
16314620
J Am Dent Assoc. 2005 Dec;136(12):1658-68
16383047